How should lipid management be considered in HIV patients on protease inhibitors?

• A. ART does not affect lipids.
• B. Use high-dose statins with protease inhibitors.
• C. Avoid all statins.
• D. ART can cause dyslipidemia; treat with statins where appropriate, mindful of interactions (e.g., avoid simvastatin with many PIs; rosuvastatin used with caution).

Answer: (D)

Managing lipids in people with HIV who are taking protease inhibitors centers on the fact that these regimens often cause dyslipidemia, and treatment must be chosen with awareness of drug interactions. Protease inhibitors can raise cholesterol and triglycerides, so lipid management is important, but not all statins behave the same when a PI is part of the regimen. Many PIs inhibit enzymes that metabolize statins, increasing the risk of statin toxicity such as myopathy or liver injury. Therefore, therapy should be tailored: statins are used when indicated, but with careful selection and dosing.

The best approach is to treat dyslipidemia with statins when appropriate, while considering interactions. Avoid using simvastatin with many boosted PIs because the interaction can dramatically raise statin levels. Rosuvastatin can be used, but with caution and at lower doses, due to potential interactions and exposure changes. Other statins, like pravastatin or fluvastatin, may be favored in certain boosted regimens because of fewer interactions. Always monitor liver enzymes and for signs of muscle toxicity, and adjust therapy based on lipid goals and tolerability.

So, ART can cause dyslipidemia; treat with statins where appropriate, mindful of interactions (e.g., avoid simvastatin with many PIs; rosuvastatin used with caution). This reflects the need to manage lipid abnormalities while navigating the interaction risks inherent to ART.